Related Experiment Video
Updated: Jul 15, 2026

Microfluidics in Assessing Platelet Function
Published on: November 8, 2024
Increased Platelet FcɣRIIa Identifies Patients at Greater Risk of Multiple Cardiovascular Events After Myocardial
David J Schneider1, Dominick J Angiolillo2, Homam Ibrahim3
1Department of Medicine, Cardiovascular Research Institute, The University of Vermont, Burlington, Vermont, USA.
Quantifying platelet FcɣRIIa (pFCG) after myocardial infarction stratifies ischemic risk. High pFCG levels are linked to increased risk of both initial and recurrent ischemic events, aiding clinical decisions.
Area of Science:
- Cardiology
- Immunology
- Biomarker Discovery
Background:
- Platelet FcɣRIIa (pFCG) quantification is crucial for stratifying ischemic risk post-myocardial infarction (MI).
- Understanding pFCG's prognostic value is essential for managing patients with type 1 MI.
Purpose of the Study:
- To evaluate platelet FcɣRIIa (pFCG) as a prognostic biomarker in patients experiencing subsequent ischemic and bleeding events.
- To assess the association between pFCG levels and the occurrence of adverse cardiovascular events.
Main Methods:
- A prospective trial enrolled 765 patients with type 1 MI and specific risk factors (age ≥65, multivessel CAD, prior MI, CKD, diabetes).
- Platelet FcɣRIIa (pFCG) was quantified using flow cytometry.
- Ischemic endpoints included MI, stroke, and death; bleeding endpoints were defined by BARC criteria.
Main Results:
- Higher pFCG levels correlated significantly with increased risk of first and multiple ischemic events, including fatal MI (P < 0.001 for trend).
- High pFCG was associated with a 2.7-fold increased risk of recurrent ischemic events between 6 months and 1 year (HR: 2.7; 95% CI: 1.82-4.02; P < 0.0001).
- pFCG levels in patients with bleeding events (without ischemia) were similar to those without any adverse events.
Conclusions:
- Elevated platelet FcɣRIIa (pFCG) is a significant predictor of both initial and recurrent ischemic events after myocardial infarction.
- pFCG may serve as a valuable biomarker to guide clinical decision-making in MI patients at high risk for ischemic complications.
Related Concept Videos
Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Formation of the Platelet Plug
As the injured blood vessel contracts, endothelial cells undergo contraction, revealing collagen fibers in the basement membrane and underlying connective tissue. Furthermore, the plasma membrane of endothelial cells becomes adhesive, preparing the site for platelet adhesion. Platelets...
Imaging Studies for Cardiovascular System VI: Calcium -Scoring CT
Coronary Artery Disease II: Pathophysiology
Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers
These markers indicate stress or strain on the heart muscle:
Natriuretic Peptides (BNP)
Cardiac myocytes produce these hormones in response to ventricular stretching...
Acute Coronary Syndrome III: Diagnostic Studies
